US group’s AIM move
A US biopharmaceutical group is developing a new platform for the delivery of protein therapy to treat chronic diseases after raising a seven-figure sum from an IPO on AIM.
News
A US biopharmaceutical group is developing a new platform for the delivery of protein therapy to treat chronic diseases after raising a seven-figure sum from an IPO on AIM.
News
News